MK-8669
Total Payments
$85,333
Transactions
27
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $69,513 | 21 | 0 |
| 2017 | $15,820 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $85,333 | 27 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Extension Trial of Deforolimus AP23573 MK-8669, an mTOR Inhibitor, for Patients with Advanced Cancer | Merck Sharp & Dohme Corporation | $69,991 | 0 |
| Phase I Parallel Protocol of MK-8669 Ridaforolimus MK- 2206 and MK-8669 Ridaforolimus MK-0752 Doublets MK-MK in Patients with Advanced Cancer | Merck Sharp & Dohme Corporation | $15,342 | 0 |
Top Doctors Receiving Payments for MK-8669
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Antonio, TX | $85,333 | 27 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $85,333
Product Information
- Type Drug
- Total Payments $85,333
- Total Doctors 0
- Transactions 27
About MK-8669
MK-8669 is a drug associated with $85,333 in payments to 0 healthcare providers, recorded across 27 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $69,513 was paid across 21 transactions to 0 doctors.
The most common payment nature for MK-8669 is "Unspecified" ($85,333, 100.0% of total).
MK-8669 is associated with 2 research studies, including "An Extension Trial of Deforolimus AP23573 MK-8669, an mTOR Inhibitor, for Patients with Advanced Cancer" ($69,991).